65.42

0.00% 0.00

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $65.42, with a volume of 528.93K. It is up +0.00% in the last 24 hours and up +17.70% over the past month. Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Previous Close:

$65.42

Open:

$65.99

24h Volume:

528.93K

Relative Volume:

0.38

Market Cap:

$6.32B

Revenue:

$7.50M

Net Income/Loss:

$-383.17M

P/E Ratio:

-13.90

EPS:

-4.7048

Net Cash Flow:

$-307.84M

1W Performance:

-4.16%

1M Performance:

+17.70%

6M Performance:

+56.66%

1Y Performance:

+110.96%

1-Day Range:

$64.27

$65.99

1-Week Range:

$64.27

$68.80

52-Week Range:

$30.00

$72.66

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

370

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	65.42	6.32B	7.50M	-383.17M	-307.84M	-4.7048
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Sep-03-25	Resumed	Wells Fargo	Overweight
May-07-25	Initiated	Chardan Capital Markets	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

Jul 22, 2026

Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution - Seeking Alpha

Jul 16, 2026

Jul 15, 2026

Price to sales forward of Xenon Pharmaceuticals Inc. – GETTEX:XP0 - TradingView

Jul 15, 2026

Jul 14, 2026

Price to sales forward of Xenon Pharmaceuticals Inc. – TRADEGATE:XP0 - TradingView

Jul 14, 2026

Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds - Sahm

Jul 14, 2026

Xenon Pharmaceuticals (XENE) Holds Near $67 as Biotech Sector Sentiment ShiftsMutual Fund Flow - dars.gov.et

Jul 14, 2026

Jul 13, 2026

Price to sales forward of Xenon Pharmaceuticals Inc. – BIVA:XENE/N - TradingView

Jul 13, 2026

Jul 08, 2026

Xenon Pharmaceuticals (XENE) Q3 2025 earnings summary - Quartr

Jul 08, 2026

Jul 07, 2026

Xenon Pharmaceuticals outlines epilepsy focus as pipeline advances - ad-hoc-news.de

Jul 07, 2026

Xenon Pharmaceuticals stock hits all-time high at 63.96 USD - Investing.com

Jul 07, 2026

Xenon Pharmaceuticals stock hits all-time high at 63.96 USD By Investing.com - Investing.com India

Jul 07, 2026

Jul 06, 2026

XENEXenon Pharmaceuticals Inc Latest SEC Filings - Finviz

Jul 06, 2026

Jul 05, 2026

Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18 - marketscreener.com

Jul 05, 2026

Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com - Investing.com Nigeria

Jul 05, 2026

Jul 04, 2026

Price to book forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView

Jul 04, 2026

Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com

Jul 04, 2026

Jul 03, 2026

We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate - Moomoo

Jul 03, 2026

Jul 02, 2026

Xenon Pharmaceuticals stock gains 22% in six months: Here's why - MSN

Jul 02, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 02, 2026

Xenon awards new hires 20,200 options and 11,850 RSUs - Stock Titan

Jul 02, 2026

Jul 01, 2026

Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView

Jul 01, 2026

Jun 30, 2026

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm

Jun 30, 2026

Jun 29, 2026

The Technical Signals Behind (XENE) That Institutions Follow - Stock Traders Daily

Jun 29, 2026

What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga

Jun 29, 2026

Jun 25, 2026

Xenon Pharmaceuticals Inc. Actuals & Estimates (FWB:XP0) - TradingView

Jun 25, 2026

Jun 24, 2026